ARIMIDEX® (anastrozole) tablets for oral administration contain 1 mg of anastrozole, a non-steroidal aromatase inhibitor.
ARIMIDEX is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.
The effectiveness of ARIMIDEX in early breast cancer is based on an analysis of recurrence-free survival in patients treated for a median of 31 months (see CLINICAL PHARMACOLOGY
-- Clinical Studies subsection). Further follow-up of study patients will be required to determine long-term outcomes.
ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor positive or hormone receptor unknown locally advanced or metastatic breast cancer.
ARIMIDEX is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX.
Media Articles Related to Arimidex (Anastrozole)
Study finds more breast cancer patients opting for mastectomy
Source: Breast Cancer News From Medical News Today [2014.11.21]
Far more breast cancer patients are choosing to undergo mastectomy, including removal of both breasts, instead of choosing breast conservation surgery even when they have early stage disease that...
NanoFlares light up individual cells if breast cancer biomarker is present
Source: Breast Cancer News From Medical News Today [2014.11.20]
Metastasis is bad news for cancer patients. Northwestern University scientists now have demonstrated a simple but powerful tool that can detect live cancer cells in the bloodstream, potentially long...
Mastectomy Rates on the Increase in Early Breast Cancer
Source: Medscape Hematology-Oncology Headlines [2014.11.19]
More and more women with early breast cancer are undergoing mastectomy, breast reconstruction, and bilateral mastectomy, latest US study confirms.
Medscape Medical News
Breast cancer; pooled analysis results of two Phase III Halaven® (eribulin) trials
Source: Breast Cancer News From Medical News Today [2014.11.18]
The results from a pooled analysis of two Phase III Halaven(R) (eribulin) trials are published in Breast Cancer Research and Treatment.
Pinpointing aggressiveness of breast cancer tumours using cutting-edge computer software
Source: Breast Cancer News From Medical News Today [2014.11.18]
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining...
Published Studies Related to Arimidex (Anastrozole)
Lipid profiles within the SABRE trial of anastrozole with and without
Lipid profiles in women with early breast cancer receiving anastrozole with or
without risedronate were examined within an international Phase III/IV study to
assess for possible treatment related changes. Postmenopausal women with hormone
receptor-positive breast cancer were assigned to 1 of 3 strata by risk of
Weight change associated with anastrozole and tamoxifen treatment in
postmenopausal women with or at high risk of developing breast cancer. 
Weight gain is commonly reported by breast cancer patients on tamoxifen or
aromatase inhibitors. Since weight gain may impact on outcome and compliance we
have prospectively assessed the effects of these agents on weight change in three
randomised trials for the treatment or prevention of breast cancer...
Pharmacokinetic comparison of 2 formulations of anastrozole (1 mg) in healthy
Korean male volunteers: a randomized, single-dose, 2-period, 2-sequence,
crossover study. 
formulations in healthy male adult volunteers... CONCLUSION: The test and reference formulations had similar PK parameters and
Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for
premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. 
goserelin for early breast cancer in the neoadjuvant setting... INTERPRETATION: Given its favourable risk-benefit profile, the combination of
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. [2011.06.10]
PURPOSE: Preoperative aromatase inhibitor (AI) treatment promotes breast-conserving surgery (BCS) for estrogen receptor (ER)-positive breast cancer. To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase III investigations... CONCLUSION: Neoadjuvant AI treatment markedly improved surgical outcomes. Ki67 and PEPI data demonstrated that the three agents tested are biologically equivalent and therefore likely to have similar adjuvant activities. LumA tumors were more likely to have favorable biomarker characteristics after treatment; however, occasional paradoxical increases in Ki67 (12% of tumors with > 5% increase after therapy) suggest treatment-resistant cells, present in some LumA tumors, can be detected by post-treatment profiling.
Clinical Trials Related to Arimidex (Anastrozole)
Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer [Completed]
The main purpose of this study is to determine the effects (good and bad) Iressa plus
anastrozole has on patients with relapsed ovarian cancer.
Gynecomastia Extension Study [Completed]
The purpose of this study is to look at the effect of anastrozole (ZD1033, Arimidex™) in
reducing gynecomastia in pubertal boys treated with placebo in Trial 1033US/0006 (another
Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer [Completed]
The purpose of this study is the initial/followed by 5 year adjuvant therapy with
Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer [Active, not recruiting]
The investigators want to know if combining Arimidex and Faslodex with Iressa will be an
effective treatment for breast cancer. They also want to know, using special tests on the
tumor, the changes that occur with the treatment so they can try to improve their treatment
for breast cancer in the future.
Open Label Arimidex in Gynecomastia [Completed]
The purpose of this study is to evaluate the safety, effectiveness, pharmacokinetics and
pharmacodynamics of anastrozole (ARIMIDEX™) in the treatment of boys with gynecomastia.
Reports of Suspected Arimidex (Anastrozole) Side Effects
Neoplasm Malignant (113),
Hot Flush (79),
Breast Cancer (78),
Pain in Extremity (67),
Drug Dose Omission (63),
Alopecia (56), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Arimidex has an overall score of 9. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Arimidex review by 45 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || post breast cancer|
|Dosage & duration:|| || 1mg taken once a day for the period of 5 years|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || Considered beneficial for post menapausal women to prevent the recurrance of breast cancer. It is a hormone blocker that stops the production of estrogen. Many breast cancer tumors are estrogen positive and thrive in the presence of estrogen.|
|Side effects:|| || I had no side effects but possible side effects are, constipation, headaches, nausea, diahrea, weight gain.|
|Comments:|| || One 1mg pill once a day for five years following treatment of breast cancer in post menapausal women.|
Page last updated: 2014-11-21